Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Rigel off after ITP data

RIGL fell $1.56 (14%) to $9.48 on 3 million shares

Read the full 107 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE